Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
REVIEWSamino acid sequence and play different roles in target interference (2).Another notable difference between Type I and III complexes is that Type III complexes lack Cas6, instead employing specialized Cas7-like subunits (Csm5 in Type III-A and Cmr1 and Cmr6 in Type III-B) to bind the 39 end of the crRNA (Fig. 1D) (11-14).Type IV CRISPR-Cas complexes, which include three subtypes (IV-A to IV-C), have a unique large subunit, Csf1, as well as subunits homologous to Cas7, Cas6, and Cas5 (Fig. 1E) (15, 16).The subunit assembly and architecture of Type IV complexes is not clear, as structures of the entire complex have not yet been determined.Homology between Cas7, Cas6, and Cas5 and the similarity of complex architectures across Class 1 systems point to a common evolutionary origin for these effector complexes.Both Type I and III systems also have Cas11, known as the "small subunit."Cas11 proteins do not share significant sequence similarity across types, but they exhibit structural homology and occupy analogous positions in Type I and III complexes (Fig. 1, C and D) (2, 7, 17).The divergence of large subunits, Cas10 and Cas8, on the other hand, suggests that they may be under greater evolutionary pressure from phage counterdefense strategies.This is consistent with the roles that Cas8 and Cas10 play
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“Transcriptional inhibition is strongest when guide RNAs target the promoter rather than the open reading frame, similar to dCas9, a cleavage-deficient mutant of Cas9 engineered to repress transcription in cells (125, 126).”
BackgroundSelf-citationEvolved Cas9 variants with broad PAM compatibility and high DNA specificity
Hu, J. H., Miller, S. M., Geurts, M. H., Tang, W., Chen, L., Sun, N., Zeina, C. M., Gao, X., Rees, H. A., Lin, Z., et al. (2018) · Nature · doi:10.1038/nature26155 · Cited by 1,552
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410 · cited 2×
“Type III Csm or Cmr complexes recognize and degrade complementary target RNA (orange lines) (1), cleave ssDNA (red lines) nonspecifically when bound to an RNA target, possibly at exposed R-loops (2), and synthesize a second messenger molecule, cyclic oligoadenylate (cOA, gray diamonds), when bound to an RNA target (3).”
BackgroundSelf-citationUnconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020) · Science · doi:10.1126/science.aba8853 · Cited by 1,233 · cited 8×
“The distinct and flexible PAM sequence requirements of Type I systems, which differ from the PAM sequences recognized by Cas9 and Cas12, broaden the array of DNA targets that can be recognized (34).”
BackgroundInfluentialRNA-Guided RNA Cleavage by a CRISPR RNA-Cas Protein Complex
Hale, C. R., Zhao, P., Olson, S., Duff, M. O., Graveley, B. R., Wells, L., Terns, R. M., & Terns, M. P. (2009) · Cell · doi:10.1016/j.cell.2009.07.040 · Cited by 1,031 · cited 1×
“RNA cleavage requires a 29-OH in the target RNA for cleavage, and the resulting termini of the reaction products have a 59-OH and either a 39-phosphate or 29,39-cyclic phosphate (14, 79).”
BackgroundNucleases: diversity of structure, function and mechanism
Yang, W. (2011) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583510000181 · Cited by 692
Type III CRISPR-Cas immunity: major differences brushed aside
Tamulaitis, G., Venclovas, Č., & Siksnys, V. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2016.09.012 · Cited by 126
Cited by
Accelerated RNA detection using tandem CRISPR nucleases
Liu, T. Y., Knott, G. J., Smock, D. C. J., Desmarais, J. J., Son, S., Bhuiya, A., Jakhanwal, S., Prywes, N., Agrawal, S., Díaz de León Derby, M., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00842-2 · Cited by 268
Self-citationRepurposing Type I-A CRISPR-Cas3 for a robust diagnosis of human papillomavirus (HPV)
Hu, T., Ji, Q., Ke, X., Zhou, H., Zhang, S., Ma, S., Yu, C., Ju, W., Lu, M., Lin, Y., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06537-3 · Cited by 24
Structure and mechanism of the type I-G CRISPR effector
Shangguan, Q., Graham, S., Sundaramoorthy, R., & White, M. F. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac925 · Cited by 24
Synthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting
Brogan, D. J., Lin, C. P., Benetta, E. D., Wang, T., Chen, F., Li, H., Lin, C., Komives, E. A., & Akbari, O. S. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169566 · Cited by 4
Metadata
- Authors
- Liu, T. Y., & Doudna, J. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 295
- Issue
- 42
- Pages
- 14473-14487
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3049491823
- Cited by
- 121
- References
- 7
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation. https://app.cochat.ai/papers/10.1074/jbc.rev120.007034
- The paper
- Liu, T. Y., & Doudna, J. A. (2020). Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.rev120.007034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.